By
Drug Target Review2025-09-23T09:00:00
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-03-28T11:38:32
Sponsored by Bio-Techne
2024-01-19T07:40:55
Sponsored by Euretos
2024-03-08T10:00:25
Sponsored by Molecular Devices
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2023-07-04T10:05:58
Sponsored by Revvity
Site powered by Webvision Cloud